CR20170443A - Análogos de nucleósido 5´-sustituidos - Google Patents
Análogos de nucleósido 5´-sustituidosInfo
- Publication number
- CR20170443A CR20170443A CR20170443A CR20170443A CR20170443A CR 20170443 A CR20170443 A CR 20170443A CR 20170443 A CR20170443 A CR 20170443A CR 20170443 A CR20170443 A CR 20170443A CR 20170443 A CR20170443 A CR 20170443A
- Authority
- CR
- Costa Rica
- Prior art keywords
- cancer
- compounds
- substituted nucleoside
- nucleoside analogs
- leukemia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Saccharide Compounds (AREA)
Abstract
La presente invención se refiere a compuestos nucleósidos 5'-sustituidos novedosos, composiciones farmacéuticas que comprenden los compuestos, y métodos de utilización de los compuestos para tratar el cáncer, más particularmente para el tratamiento del cáncer, en particular los glioblastomas, melanoma, sarcomas, cáncer gástrico, cáncer de páncreas , colangiocarcinoma, cáncer de vejiga, cáncer de mama, cáncer de pulmón de células no pequeñas, leucemias, incluyendo leucemia mieloide aguda y los linfomas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15382225 | 2015-05-04 | ||
PCT/US2016/029475 WO2016178870A1 (en) | 2015-05-04 | 2016-04-27 | 5'-substituted nucleoside analogs |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20170443A true CR20170443A (es) | 2017-11-07 |
Family
ID=53177322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20170443A CR20170443A (es) | 2015-05-04 | 2016-04-27 | Análogos de nucleósido 5´-sustituidos |
Country Status (25)
Country | Link |
---|---|
US (1) | US9840532B2 (es) |
EP (1) | EP3292128A1 (es) |
JP (2) | JP6181889B1 (es) |
KR (1) | KR20170132871A (es) |
CN (1) | CN107580602A (es) |
AR (1) | AR104326A1 (es) |
AU (1) | AU2016258485A1 (es) |
BR (1) | BR112017020336A2 (es) |
CA (1) | CA2981097A1 (es) |
CL (1) | CL2017002637A1 (es) |
CO (1) | CO2017010727A2 (es) |
CR (1) | CR20170443A (es) |
DO (1) | DOP2017000255A (es) |
EA (1) | EA201792169A1 (es) |
EC (1) | ECSP17072987A (es) |
HK (1) | HK1244007A1 (es) |
IL (1) | IL254409A0 (es) |
MA (1) | MA42036A (es) |
MX (1) | MX2017014001A (es) |
PE (1) | PE20180231A1 (es) |
PH (1) | PH12017502002A1 (es) |
SG (1) | SG11201708345XA (es) |
TN (1) | TN2017000459A1 (es) |
TW (1) | TWI615400B (es) |
WO (1) | WO2016178870A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU20170105A7 (es) * | 2015-02-24 | 2017-10-05 | Pfizer | Derivados de nucleosidos sustituidos útiles como agentes antineoplásicos |
JP7043080B2 (ja) * | 2017-01-27 | 2022-03-29 | 国立大学法人 宮崎大学 | がんに対する有効性判定キット及びがんに対する有効性判定方法 |
WO2018152548A1 (en) | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
WO2018152501A1 (en) | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
WO2018160855A1 (en) | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
PL3665179T3 (pl) | 2017-08-09 | 2021-11-29 | Prelude Therapeutics, Incorporated | Selektywne inhibitory metylotransferazy argininowej białek 5 (prmt5) |
CN111542525B (zh) * | 2017-10-26 | 2023-06-27 | 普莱鲁德疗法有限公司 | 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂 |
RS63623B1 (sr) | 2017-12-13 | 2022-10-31 | Lupin Ltd | Supstituisana biciklična heterociklična jedinjenja kao inhibitori prmt5 |
ES2963436T3 (es) | 2018-03-14 | 2024-03-27 | Prelude Therapeutics Inc | Inhibidores selectivos de la proteína arginina metiltransferasa 5 (PRMT5) |
US10711007B2 (en) | 2018-03-14 | 2020-07-14 | Prelude Therapeutics Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
JP7337539B2 (ja) * | 2018-06-21 | 2023-09-04 | メディヴィル・アクチエボラーグ | 白血病療法のための塩基修飾シチジンヌクレオチド |
EP3833669A4 (en) * | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | PRMT5 INHIBITORS |
BR112021015796A2 (pt) * | 2019-02-13 | 2021-10-13 | Prelude Therapeutics, Incorporated | Inibidor seletivo de proteína arginina metiltransferase 5 (prmt5) |
CN114026094B (zh) | 2019-06-10 | 2024-06-25 | 印度鲁宾有限公司 | Prmt5抑制剂 |
MX2022004917A (es) | 2019-10-22 | 2022-08-04 | Lupin Ltd | Combinación farmacéutica de inhibidores de prmt5. |
MX2022006735A (es) | 2019-12-03 | 2022-07-21 | Lupin Ltd | Análogos de nucleósidos sustituidos como inhibidores de la prmt5. |
GB202117230D0 (en) | 2021-11-29 | 2022-01-12 | Argonaut Therapeutics Ltd | Peptide vaccine |
GB202203588D0 (en) | 2022-03-15 | 2022-04-27 | Argonaut Therapeutics Ltd | Cancer diagnostic |
CN116211869B (zh) * | 2022-12-07 | 2023-08-01 | 浙江省肿瘤医院 | 含dna损伤修复抑制剂的药物混合物及混合方法、用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL354094A1 (en) * | 1999-08-27 | 2003-12-29 | Icn Pharmaceuticals, Inc.Icn Pharmaceuticals, Inc. | Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
NZ544187A (en) * | 2005-12-15 | 2008-07-31 | Ind Res Ltd | Deazapurine analogs of 1'-aza-l-nucleosides |
US9044432B2 (en) | 2009-12-22 | 2015-06-02 | Ohio State Innovation Foundation | Compositions and methods for cancer detection and treatment |
US9416154B2 (en) * | 2011-07-13 | 2016-08-16 | Merck Sharp & Dohme Corp. | 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
US10118918B2 (en) | 2012-12-21 | 2018-11-06 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
CA2899363A1 (en) * | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
WO2014100695A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
CA2894130A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
PT2935222T (pt) | 2012-12-21 | 2018-12-10 | Epizyme Inc | Inibidores de prmt5 e seus usos |
JP2016511744A (ja) | 2012-12-21 | 2016-04-21 | エピザイム,インコーポレイティド | Prmt5を阻害する方法 |
CU20170105A7 (es) | 2015-02-24 | 2017-10-05 | Pfizer | Derivados de nucleosidos sustituidos útiles como agentes antineoplásicos |
-
2016
- 2016-04-20 AR ARP160101081A patent/AR104326A1/es unknown
- 2016-04-22 TW TW105112724A patent/TWI615400B/zh not_active IP Right Cessation
- 2016-04-27 WO PCT/US2016/029475 patent/WO2016178870A1/en active Application Filing
- 2016-04-27 BR BR112017020336-7A patent/BR112017020336A2/pt not_active Application Discontinuation
- 2016-04-27 SG SG11201708345XA patent/SG11201708345XA/en unknown
- 2016-04-27 KR KR1020177031713A patent/KR20170132871A/ko active Search and Examination
- 2016-04-27 AU AU2016258485A patent/AU2016258485A1/en not_active Abandoned
- 2016-04-27 TN TNP/2017/000459A patent/TN2017000459A1/en unknown
- 2016-04-27 US US15/139,370 patent/US9840532B2/en not_active Expired - Fee Related
- 2016-04-27 CR CR20170443A patent/CR20170443A/es unknown
- 2016-04-27 JP JP2016575652A patent/JP6181889B1/ja not_active Expired - Fee Related
- 2016-04-27 MX MX2017014001A patent/MX2017014001A/es unknown
- 2016-04-27 EA EA201792169A patent/EA201792169A1/ru unknown
- 2016-04-27 MA MA042036A patent/MA42036A/fr unknown
- 2016-04-27 CA CA2981097A patent/CA2981097A1/en not_active Abandoned
- 2016-04-27 EP EP16720676.2A patent/EP3292128A1/en not_active Withdrawn
- 2016-04-27 CN CN201680025080.3A patent/CN107580602A/zh active Pending
- 2016-04-27 PE PE2017002330A patent/PE20180231A1/es not_active Application Discontinuation
-
2017
- 2017-02-15 JP JP2017025494A patent/JP2017125029A/ja active Pending
- 2017-09-11 IL IL254409A patent/IL254409A0/en unknown
- 2017-10-17 CL CL2017002637A patent/CL2017002637A1/es unknown
- 2017-10-20 CO CONC2017/0010727A patent/CO2017010727A2/es unknown
- 2017-10-30 DO DO2017000255A patent/DOP2017000255A/es unknown
- 2017-11-01 EC ECIEPI201772987A patent/ECSP17072987A/es unknown
- 2017-11-03 PH PH12017502002A patent/PH12017502002A1/en unknown
-
2018
- 2018-03-15 HK HK18103599.9A patent/HK1244007A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
DOP2017000255A (es) | 2018-01-15 |
PH12017502002A1 (en) | 2018-03-26 |
JP2017525667A (ja) | 2017-09-07 |
TWI615400B (zh) | 2018-02-21 |
US20160326208A1 (en) | 2016-11-10 |
TN2017000459A1 (en) | 2019-04-12 |
JP2017125029A (ja) | 2017-07-20 |
SG11201708345XA (en) | 2017-11-29 |
AR104326A1 (es) | 2017-07-12 |
IL254409A0 (en) | 2017-11-30 |
HK1244007A1 (zh) | 2018-07-27 |
ECSP17072987A (es) | 2018-02-28 |
EA201792169A1 (ru) | 2018-03-30 |
WO2016178870A1 (en) | 2016-11-10 |
JP6181889B1 (ja) | 2017-08-16 |
AU2016258485A1 (en) | 2017-10-12 |
CN107580602A (zh) | 2018-01-12 |
CO2017010727A2 (es) | 2018-01-31 |
EP3292128A1 (en) | 2018-03-14 |
CL2017002637A1 (es) | 2018-04-20 |
PE20180231A1 (es) | 2018-01-31 |
MA42036A (fr) | 2018-03-14 |
TW201712022A (zh) | 2017-04-01 |
US9840532B2 (en) | 2017-12-12 |
CA2981097A1 (en) | 2016-11-10 |
MX2017014001A (es) | 2018-03-16 |
KR20170132871A (ko) | 2017-12-04 |
BR112017020336A2 (pt) | 2019-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017002637A1 (es) | Compuestos nucleósidos 5'-sustituidos. | |
UY37124A (es) | Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos | |
CO2019008783A2 (es) | Compuestos dinucleotidos ciclicos para el tratamiento del cancer | |
DOP2020000050A (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
CL2019001369A1 (es) | Composición farmacéutica para prevenir o tratar el cáncer de mama, incluido el polimorfo cristalino del hexoxido tetraarsenico y el método para producirlo. | |
PH12017501413A1 (en) | Substituted nucleoside derivatives useful as anticancer agents | |
ECSP18049420A (es) | Composiciones novedosas, usos y métodos para hacerlas | |
PH12017502255A1 (en) | Nrf2 regulators | |
CO2017000359A2 (es) | Compuestos derivados de piridina sustituidos como inhibidores de histonas desmetilasa | |
ECSP20033467A (es) | Compuestos macrocíclicos para tratar enfermedades | |
CR20160501A (es) | Derivados de quinoxalina útiles como amortiguadores del receptor del factor de crecimiento de fibroblastos (fgfr) cinasa | |
MY198613A (en) | Nitrobenzyl derivatives of anti-cancer agents | |
UY36419A (es) | Composiciones farmacéuticas que contienen anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda | |
CL2012000324A1 (es) | Compuestos derivados de benciimidazol sustituido con un grupo pirazol sustituido, inhibidor de quinasa fgfr; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
DOP2018000008A (es) | Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r) | |
ECSP17020172A (es) | Inhibidores de histona desmetilasa | |
UY36758A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
MX2017001459A (es) | Sintesis de fosforamidatos. | |
JOP20190163B1 (ar) | منشط nrf2 | |
SV2016005310A (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
AR104220A1 (es) | Reducción de la aversión al sabor del cpc mediante la reducción de la activación del cpc de los receptores de trpa1, receptores de trpv1, o ambos | |
DOP2017000196A (es) | Derivados de tetrahidropiranil benzamida | |
UY37139A (es) | Monotartrato de vinorelbina y su uso farmacéutico | |
ECSP17046657A (es) | Síntesis total de trioxacarcina dc-45-a2 y preparación de análogos de trioxacarcina |